表紙
市場調査レポート

Kappaproct(潰瘍性大腸炎) - 予測と市場分析

Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 300494
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Kappaproct(潰瘍性大腸炎) - 予測と市場分析 Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022
出版日: 2014年02月28日 ページ情報: 英文 59 Pages
概要

2012年〜2022年の潰瘍性大腸炎(UC)治療薬市場は、Johnson & Johnson(Simponi)、武田薬品工業(Entyvio)の参入によって大幅な成長が予測され、主要国(米国、EU5ヶ国、日本、カナダ)において、生物製剤による治療を受ける患者数が増加すると見込まれています。また、UCのブロックバスター薬(Remicade、Humira)が米国で特許失効となるため、バイオシミラー(バイオ後続品)の発売が、市場に影響を与える可能性があります。

当レポートでは、UC治療薬であるKappaproctについて調査分析し、疾病の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
  • 症状

第4章 疾病の管理

  • 診断と治療の概要

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 機会とアンメットニーズ

  • 概要
  • アンメットニーズ
  • アンメットニーズのギャップ分析
  • 病気の重症度と大腸癌のバイオマーカーに基づく予後の方法
  • 難治性の予測因子

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤

第8章 Kappaproct(DIMS 0150)

  • 概要
  • 効能
  • 安全性
  • 投与・処方
  • 潜在的な臨床的位置付け
  • 潜在的な商業的位置付け
  • 価格と償還
  • SWOT分析
  • 予測

第9章 付録

図表

目次
Product Code: GDHC344DFR

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

InDeX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of immunological treatments for diseases with a high unmet need. The company is dedicated to developing personalized treatments and diagnostic assays that will allow physicians to predict which patient populations will respond to specific biologics. InDeX developed Kappaproct with the goal of addressing a significant unmet need in severe UC patients, which is the lack of an effective treatment.

Scope

  • Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Kappaproct including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Kappaproct for the top five countries from 2012 to 2022.
  • Sales information covered for France, Germany, Italy, Spain and the UK.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Kappaproct performance
  • Obtain sales forecast for Kappaproct from 2012-2022 in the top five countries (France, Germany, Italy, Spain and the UK)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
    • 3.2.1. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Curative Therapy for Severe UC Patients
    • 6.2.2. Diagnostic Markers for Disease Severity
    • 6.2.3. Personalized Therapy
    • 6.2.4. A Replacement for Steroids
    • 6.2.5. Novel Oral Drug Formulations
    • 6.2.6. Preventative Medicine for Lowering the Associated Colorectal Cancer Risk
    • 6.2.7. Improved Management of Infectious Adverse Events
  • 6.3. Unmet Needs Gap Analysis
  • 6.4. Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools
  • 6.5. Predictors of Medically-Refractory Disease

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Kappaproct (DIMS 0150)

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed UC Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Author
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Genetic Factors That Confer a Predisposition to UC
  • Table 2: Typical Symptoms of UC
  • Table 3: Truelove and Witts UC Severity Index
  • Table 4: UCDAI
  • Table 5: Treatment Guidelines for UC Used in the 10MM
  • Table 6: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013
  • Table 7: Leading Treatments for UC, 2014
  • Table 8: Overall Unmet Needs - Current Level of Attainment
  • Table 9: Corticosteroid Long-Term Side Effects
  • Table 10: Clinical Unmet Needs in UC - Gap Analysis, 2013
  • Table 11: Prognostic Markers in UC
  • Table 12: UC - Pre-Registration and Phase III Pipeline, 2014
  • Table 13: Comparison of Therapeutic Classes in Development for UC, 2014
  • Table 14: Product Profile - Kappaproct
  • Table 15: Results of Phase IIb Trial of Kappaproct in the Induction of Remission in UC
  • Table 16: Kappaproct SWOT Analysis, 2014
  • Table 17: Global Sales Forecasts ($m) for Kappaproct, 2012-2022
  • Table 18: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC
  • Figure 2: UC Disease Management Flowchart
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents UC, 2012-2022
Back to Top